The dual modulation of FXR and ASK1 is considered a promising therapeutic strategy for metabolic dysfunction-associated fatty liver disease (MAFLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.